Workflow
东宝生物: 招商证券股份有限公司关于包头东宝生物技术股份有限公司2025年半年度跟踪报告
Zheng Quan Zhi Xing·2025-09-05 16:13

Group 1 - The company is under the sponsorship of China Merchants Securities Co., Ltd. for its operations and compliance [1] - The company has conducted regular reviews of its information disclosure documents and has established necessary regulations to prevent resource occupation by related parties [1][2] - The company reported a revenue of 369.06 million yuan, a decrease of 16.93% compared to the previous year, and a net profit attributable to shareholders of 36.97 million yuan, down 28.00% year-on-year [2][3] Group 2 - The company has held two shareholder meetings and two board meetings, reviewing all relevant documents [1] - The company has conducted one on-site inspection, and the report was submitted according to regulations [1] - The company has committed to fulfilling promises regarding competition, related transactions, and fund occupation, with no reported issues [2][3]